KRAS and cancer: Concurrent pharmacologic targets of the RAF/MEK/ERK and PI3K/AKT/mTOR pathways have been reported in KRAS-driven cancer models, but clinically this strategy has been limited by additive toxicity (Collisson et al., 2012).